Neurocrine Biosciences (NBIX) Competitors $125.01 +0.84 (+0.68%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NBIX vs. ALNY, BIIB, UTHR, INCY, EXEL, BMRN, EXAS, HALO, RGEN, and MDGLShould you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Repligen (RGEN), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Neurocrine Biosciences vs. Its Competitors Alnylam Pharmaceuticals Biogen United Therapeutics Incyte Exelixis BioMarin Pharmaceutical Exact Sciences Halozyme Therapeutics Repligen Madrigal Pharmaceuticals Neurocrine Biosciences (NASDAQ:NBIX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends. Which has preferable valuation and earnings, NBIX or ALNY? Neurocrine Biosciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurocrine Biosciences$2.41B5.13$341.30M$2.9542.38Alnylam Pharmaceuticals$2.35B16.92-$278.16M-$2.09-145.78 Does the MarketBeat Community prefer NBIX or ALNY? Alnylam Pharmaceuticals received 123 more outperform votes than Neurocrine Biosciences when rated by MarketBeat users. However, 77.70% of users gave Neurocrine Biosciences an outperform vote while only 76.34% of users gave Alnylam Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNeurocrine BiosciencesOutperform Votes104577.70% Underperform Votes30022.30% Alnylam PharmaceuticalsOutperform Votes116876.34% Underperform Votes36223.66% Do insiders & institutionals believe in NBIX or ALNY? 92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 4.8% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, NBIX or ALNY? Neurocrine Biosciences has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Is NBIX or ALNY more profitable? Neurocrine Biosciences has a net margin of 14.49% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Neurocrine Biosciences' return on equity of 13.38% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Neurocrine Biosciences14.49% 13.38% 9.73% Alnylam Pharmaceuticals -12.37%N/A -6.83% Do analysts rate NBIX or ALNY? Neurocrine Biosciences currently has a consensus price target of $162.00, suggesting a potential upside of 29.59%. Alnylam Pharmaceuticals has a consensus price target of $319.58, suggesting a potential upside of 4.89%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Neurocrine Biosciences is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurocrine Biosciences 0 Sell rating(s) 3 Hold rating(s) 19 Buy rating(s) 0 Strong Buy rating(s) 2.86Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.77 Does the media prefer NBIX or ALNY? In the previous week, Alnylam Pharmaceuticals had 4 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 21 mentions for Alnylam Pharmaceuticals and 17 mentions for Neurocrine Biosciences. Alnylam Pharmaceuticals' average media sentiment score of 1.17 beat Neurocrine Biosciences' score of 0.82 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryNeurocrine Biosciences beats Alnylam Pharmaceuticals on 12 of the 18 factors compared between the two stocks. Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBIX vs. The Competition Export to ExcelMetricNeurocrine BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.37B$3.12B$5.61B$8.62BDividend YieldN/A1.57%5.28%4.18%P/E Ratio38.0032.9027.1419.96Price / Sales5.13466.20411.83157.63Price / Cash34.35168.6838.2534.64Price / Book4.813.427.064.69Net Income$341.30M-$72.35M$3.23B$248.14M7 Day Performance0.32%7.27%2.67%2.39%1 Month Performance3.80%17.53%8.82%6.05%1 Year Performance-7.14%-17.27%31.44%13.60% Neurocrine Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBIXNeurocrine Biosciences4.8954 of 5 stars$125.01+0.7%$162.00+29.6%-6.7%$12.37B$2.41B38.001,200Analyst RevisionALNYAlnylam Pharmaceuticals4.2819 of 5 stars$306.09+0.5%$319.17+4.3%+90.9%$39.91B$2.35B-141.052,000Positive NewsAnalyst ForecastBIIBBiogen4.7612 of 5 stars$131.14+1.0%$191.30+45.9%-41.1%$19.22B$9.82B11.728,720Trending NewsAnalyst ForecastUTHRUnited Therapeutics4.9935 of 5 stars$325.48+2.1%$393.00+20.7%+0.3%$14.68B$2.99B14.29980Positive NewsAnalyst ForecastInsider TradeAnalyst RevisionINCYIncyte4.4844 of 5 stars$65.31+0.4%$73.60+12.7%+15.8%$12.64B$4.41B241.902,320EXELExelixis4.4661 of 5 stars$42.88-0.4%$38.94-9.2%+88.1%$11.69B$2.30B24.231,220Positive NewsAnalyst ForecastBMRNBioMarin Pharmaceutical4.947 of 5 stars$57.05-1.8%$93.45+63.8%-31.8%$10.94B$2.95B25.933,080Positive NewsAnalyst RevisionEXASExact Sciences4.5971 of 5 stars$56.13-0.3%$70.90+26.3%+32.1%$10.59B$2.83B-10.086,400Positive NewsHALOHalozyme Therapeutics4.914 of 5 stars$55.64-0.8%$61.90+11.3%+7.9%$6.86B$1.08B16.22390Positive NewsRGENRepligen4.7305 of 5 stars$118.57+0.4%$173.25+46.1%-6.2%$6.66B$650.43M-232.492,020MDGLMadrigal Pharmaceuticals4.3388 of 5 stars$272.67-0.9%$416.33+52.7%+0.8%$6.05B$317.38M-10.8790Positive NewsAnalyst Revision Related Companies and Tools Related Companies Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Incyte Competitors Exelixis Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Halozyme Therapeutics Competitors Repligen Competitors Madrigal Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBIX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NBIX Stock Free NBIX Stock Alerts